On flow cytometry in myelodysplastic syndromes, with caveats

Leukemia Research

Volumn 32, Issue 2, 2008, Pages 209-210

  Wells, Denise A ^a   Ogata, Kiyoyuki ^b  

^a HEMATOLOGICS INC   (United States)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD11 ANTIGEN; CD16 ANTIGEN;

BONE MARROW BIOPSY; CYTOPENIA; DISEASE CLASSIFICATION; DISEASE COURSE; DNA POLYMORPHISM; EDITORIAL; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; MYELOBLAST; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

FLOW CYTOMETRY; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 38949124711     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.07.024     Document Type: Editorial

References (9)

1. Bowen K.L., and Davis B.H. Abnormal patterns of expression of CD16 (FcR-III) and CD11b (CRIII) in the bone marrow of patients with myelodysplastic syndrome. Lab Hematol 3 (1997) 292-298
2. Stetler-Stevenson M., Arthur D.C., Jabbour N., et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98 4 (2001) 979-987
3. Wells D.A., Benesch M., Loken M.R., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 102 1 (2003) 394-403
4. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 6 (1997) 2079-2088
5. Kussick S.J., Fromm J.R., Rossini A., et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 124 2 (2005) 170-181
6. Ogata K., Kishikawa Y., Satoh C., et al. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 108 3 (2006) 1037-1044
7. Valent P., Horny H.-P., Bennett J.M., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 31 6 (2007) 727-736
8. Wimazal F., Fonatsch C., Thalhammer R., et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res (2007)
9. Deeg Joachim H., Jiang P.Y., Holmberg L.A., et al. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res 28 11 (2004) 1177 (0145-2126)